Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• High-dose enoximone (a phosphodiesterase inhibitor) improves exercise capacity in heart failure but increases mortality.
• The effects of low-dose enoximone on exercise capacity and safety in chronic heart failure (CHF) remain unevaluated.

Purpose of the Study:

• To assess the impact of low-dose enoximone on exercise capacity in patients with CHF.
• To evaluate the safety profile, including adverse events and arrhythmias, of low-dose enoximone treatment.

Main Methods:

• Prospective, double-blind, placebo-controlled, multicenter trial involving 105 patients with NYHA class II-III CHF.
• Patients received placebo, enoximone 25 mg, or enoximone 50 mg orally three times daily for 12 weeks.
• Exercise capacity was measured via maximal treadmill testing; quality of life and arrhythmias were also assessed.

Main Results:

• Both 25 mg and 50 mg doses of enoximone significantly improved exercise capacity at 12 weeks (p=0.013 and p=0.003, respectively).
• No increase in ventricular arrhythmias was observed; mortality was lower in enoximone groups compared to placebo.
• Enoximone treatment favored improvements in dyspnea and overall clinical status.

Conclusions:

• Low-dose enoximone (25 mg and 50 mg three times daily) effectively enhances exercise capacity in CHF patients.
• Treatment with low-dose enoximone is safe and does not increase adverse events over a 12-week period.